Boehringer Ingelheim International Gmbh

Centrexion Therapeutics Corporation

Janet Rachel Nicholson

Doris Riether

Achim Sauer

Florian Paul Christian Binder

Henri Doods

Stephan Georg Mueller

Niklas Heine

Marco Ferrara

Uta Friederike Lessel

Anton Pekcec

Stefan Scheuerer

Henri Doobs

Stephan George Mueller

Florian Binder

Uta Lessel

This invention relates to novel (Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles and their use as CB2 cannabinoid receptor agonists, pharmaceutical compositions containing the same, and their use for the treatment of CB2 receptor mediated disorders or conditions.

(cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles

(Cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles

This invention relates to compounds of formula (I), a process for their preparation, pharmaceutical compositions containing them and their use in the treatment of conditions having an association with the orexin sub-type 1 receptor. Ar, R, R, R, R, R, Rand Rhave meanings given in the description. 

N-[(pyridyloxy)propanyl]benzamides

This invention relates to compounds of formula (I), a process for their preparation, pharmaceutical compositions containing them and their use in the treatment of conditions having an association with the orexin sub-type 1 receptor. Arand Arhave meanings given in the description. 

N-[(heteroaryloxy)propanyl]heteroaryl carboxamides as antagonists of orexin subtype 1 receptor activity

The present invention relates to novel N-[(Pyrimidinylamino)propanyl]- and N-[(Pyridinylamino)propanyl]arylcarboxamide derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment or prevention of conditions having an association with the orexin sub-type 1 receptor.

N-[(Pyrimidinylamino)propanyl]-and N-[(Pyridinylamino)-propanyl]arylcarboxamides

This invention relates to compounds of formula I a process for their preparation, pharmaceutical compositions containing them and their use in the treatment of conditions having an association with the orexin sub-type 1 receptor. Ar, R, Rand Rhave meanings given in the description.

N-[(pyrazinyloxy)propanyl]benzamides as antagonists of orexin subtype 1 receptor activity

This invention relates to compounds of formula (I), a process for their preparation, pharmaceutical compositions containing them and their use in the treatment of conditions having an association with the orexin sub-type 1 receptor. Ar, R, R, R, R, Rhave meanings given in the description. 

N-[(pyrimidinyloxy)propanyl]benzamides

The present invention relates to novel N-[(Pyrimidinylamino)propanyl]- and N-[(Pyrazinylamino)-propanyl]arylcarboxamide derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, particularly in the treatment or prevention of conditions having an association with the orexin sub-type 1 receptor.

N-[(pyrimidinylamino)propanyl]-and N[(pyrazinylamino)proppanyl]arylcarboxamides

This invention relates to novel (Cyano-dimethyl-methyl)-isoxazolesand-[1,3,4]thiadiazoles and their use as CB2 cannabinoid receptor agonists, pharmaceutical compositions containing the same, and their use for the treatment of CB2 receptor mediated disorders or conditions.

Disclosed are (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles and their use as CB2 cannabinoid receptor agonists, pharmaceutical compositions containing the same, and their use for the treatment of CB2 receptor mediated disorders or conditions.

Growing community of inventors

Oberhoefen, Germany

Janet Rachel Nicholson